0000000000901934

AUTHOR

Francesco Blasi

showing 28 related works from this author

Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study (vol 19, 171, 2019)

2019

Background: Chronic Obstructive Pulmonary Disease (COPD) encompasses various phenotypes that severely limit the applicability of precision respiratory medicine. The present investigation is aimed to assess the circadian rhythm of symptoms in pre-defined clinical COPD phenotypes and its association with health-related quality of life (HR-QoL), the quality of sleep and the level of depression/anxiety in each clinical phenotype. Methods: The STORICO (NCT03105999) Italian observational prospective cohort study enrolled COPD subjects. A clinical diagnosis of either chronic bronchitis (CB), emphysema (EM) or mixed COPD-asthma (MCA) phenotype was made by clinicians at enrollment. Baseline early-mo…

COPDnoctunal symptoms
researchProduct

Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage.

2014

International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studi…

medicine.medical_specialtyCombination therapyAsthma exacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerAsthma controlFluticasone propionate/formoterolForced Expiratory VolumeFormoterol FumarateInternal MedicineMedicineHumansAnti-Asthmatic AgentsAsthma exacerbationsParticle SizeIntensive care medicineAsthmaFluticasonebusiness.industryInhalerNebulizers and VaporizersFixed-combination therapyAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhaler; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; Ethanolamines; Fluticasone; Forced Expiratory Volume; Formoterol Fumarate; Humans; Nebulizers and Vaporizers; Particle Size; Quality of Life; Treatment Outcomemedicine.diseaseSingle-aerosol inhalerAsthmaBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilityAsthma control Asthma exacerbations Fixed-combination therapy Fluticasone propionate/formoterol Single-aerosol inhalerEthanolaminesAnesthesiaAsthma exacerbations; Asthma control; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerQuality of LifeFluticasoneFormoterol FumarateFormoterolbusinessmedicine.drugEuropean journal of internal medicine
researchProduct

Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study

2022

High-flow nasal therapy (HFNT) provides several pathophysiological benefits in chronic respiratory disorders. We aimed to evaluate the effectiveness of long-term HFNT in patients with bronchiectasis (BE). Methods: This is a retrospective bicentric case-control study of outpatients with BE on optimized medical treatment with a severe exacerbation requiring hospitalization in the previous year. Patients on long-term home HFNT (cases) and patients on optimized medical treatment alone (controls) were matched by age, sex, bronchiectasis severity index, and exacerbations in the previous year. Data on BE exacerbations, hospitalizations/year, mucus features, respiratory symptoms, and pulmonary func…

bronchiectasis; exacerbation; high-flow nasal cannula; high-flow nasal therapy; hospitalization; mucus;exacerbationbronchiectasis; exacerbation; high-flow nasal cannula; high-flow nasal therapy; hospitalization; mucushigh-flow nasal cannulahigh-flow nasal cannula; high-flow nasal therapy; bronchiectasis; mucus; exacerbation; hospitalizationbronchiectasismucusSettore MED/10 - Malattie dell'Apparato Respiratoriohigh-flow nasal therapyGeneral Medicinehospitalization
researchProduct

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

2020

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored al…

ISAR International Severe Asthma RegistrySHARPPediatricsSevere asthmaSA severe asthmaBiologics Oral corticosteroids Real-life Registr Severe asthmaOmalizumabforced expiratory volume in the 1st secondFood &ampGrading of Recommendations Assessmentchronic rhinosinusitis with nasal polyposisFEV1chemistry.chemical_compound0302 clinical medicineQuality of lifeEMAReal WorldEuropean Medicines AgencyBiologics; Oral corticosteroids; Real-life; Registr; Severe asthmaOral corticosteroidsFDA Food & Drug AdministrationImmunology and Allergy030223 otorhinolaryngologySevere Heterogeneous Asthma Research collaborationmusculoskeletal neural and ocular physiologyReal-lifeCRSwNPOCSsBenralizumabDupilumabCRSwNP chronic rhinosinusitis with nasal polyposisGRADESHARP Severe Heterogeneous Asthma Research collaboration Patient-centredSevere Asthma Network in ItalyFDAmedicine.drugPulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyDrug AdministrationGINA Global Initiative for AsthmaRW Real WorldImmunologymacromolecular substancesRWSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologicsInternational Severe Asthma RegistryISAR03 medical and health sciencesSADisease registrySARP Severe Asthma Research ProgramPatient-centredmedicineAsthmabusiness.industrySettore MED/09 - MEDICINA INTERNASANI Severe Asthma Network in ItalySANIBiological productmedicine.diseaseOCSs Oral CorticoSteroidsGINASARPSevere Asthma Research ProgramFEV1 forced expiratory volume in the 1st second030228 respiratory systemchemistrynervous systemRegistrEMA European Medicines AgencyDevelopment and EvaluationSevere asthma Biologics Oral corticosteroids Real-life Registrbusinesslcsh:RC581-607Global Initiative for AsthmaMepolizumabGRADE Grading of Recommendations Assessment Development and Evaluation
researchProduct

What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis

2020

Abstract Background The choice of inhaler device for asthma patients depends upon multiple attributes. We investigated factors that may drive general practitioners (GPs) and respiratory specialists in the prescription of inhaler devices for asthma patients who initiated inhalation therapy. Methods We retrospectively analysed prescriptions by GPs and respiratory specialists to asthma patients commencing inhaled corticosteroid/long-acting β2-agonist combination therapy available as both pressurised metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs). Patient characteristics were compared by device and multivariate analysis was used to model the likelihood of receiving a pMDI as oppos…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyMultivariate analysisSettore MED/10 - Malattie Dell'Apparato RespiratorioGeneral practitioner03 medical and health sciencesdry powder inhaler0302 clinical medicineInhalersAdrenal Cortex HormonesAdrenergic beta-2 Receptor AntagonistsAsthma controlGeneral practitionersAdministration InhalationRetrospective analysisMedicine030212 general & internal medicineMetered Dose InhalersMedical prescriptionAsthmaRetrospective Studiesbusiness.industryInhalerdry powder inhalersInhalerOdds ratiomedicine.diseaseConfidence intervalAsthmaPressurised metered-dose inhalerAsthma; dry powder inhalers; General practitioners; Inhalers; Pressurised metered-dose inhalers; Respiratory specialistsPrescriptions030228 respiratory systemRespiratory specialistsInhalationDelayed-Action PreparationsEmergency medicineAdministrationPressurised metered-dose inhalersbusinessAsthma; dry powder inhalers; General practitioners; Inhalers; Pressurised metered-dose inhalers; Respiratory specialists; Administration Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagonists; Asthma; Delayed-Action Preparations; Retrospective Studies; Dry Powder Inhalers; Metered Dose Inhalers; Prescriptions
researchProduct

WITHDRAWN: Scaling up strategies of the Chronic Respiratory Disease programme of the European Innovation Partnership on Active and Healthy Ageing (Ac…

2017

Gerontologymedicine.medical_specialtybusiness.industryRespiratory diseaseAlternative medicinemedicine.disease03 medical and health sciences0302 clinical medicine030228 respiratory systemGeneral partnershipAction planmedicineGeneral Earth and Planetary Sciences030212 general & internal medicineHealthy ageingbusinessGeneral Environmental ScienceAlergologia Polska - Polish Journal of Allergology
researchProduct

Clinical Evolution and Quality of Life in Clinically Based COPD Chronic Bronchitic and Emphysematous Phenotypes: Results from the 1-Year Follow-Up of…

2021

Francesco Blasi, 1, 2 Raffaele Antonelli Incalzi, 3 Giorgio Walter Canonica, 4 Pietro Schino, 5 Giuseppina Cuttitta, 6 Alessandro Zullo, 7 Alessandra Ori, 7 Nicola Scichilone 8 On behalf of STORICO study group 1Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, 20122, Italy; 2Department of Pathophysiology and Transplantation, University of Milan, Milan, 20122, Italy; 3University Biomedical Campus of Rome, Rome, 00128, Italy; 4Personalized Medicine Asthma & Allergy Clinic Humanitas University Humanitas research Hospital Rozzano, Rozzano (Milan), 20089, Italy; 5Miulli Hospital, Acquaviva …

Chronic bronchitismedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioDiseases of the respiratory systemPulmonary Disease Chronic ObstructiveClinical evolution Clinical phenotype COPD Quality of life Follow-Up Studies Humans Phenotype Quality of Life Bronchitis Chronic Emphysema Pulmonary Disease Chronic Obstructive ItalyQuality of lifeDLCOInternal medicinemedicineHumansCOPDDepression (differential diagnoses)Original ResearchEmphysemaclinical evolutionCOPDRC705-779business.industryMinimal clinically important differenceGeneral Medicineclinical phenotypemedicine.diseaseBronchitis ChronicPulmonologyPhenotypeItalyquality of lifeAnxietymedicine.symptombusinessFollow-Up StudiesInternational journal of chronic obstructive pulmonary disease
researchProduct

Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19

2021

To understand how a protective immune response against SARS-CoV-2 develops over time, we integrated phenotypic, transcriptional and repertoire analyses on PBMCs from mild and severe COVID-19 patients during and after infection, and compared them to healthy donors (HD). A type I IFN-response signature marked all the immune populations from severe patients during the infection. Humoral immunity was dominated by IgG production primarily against the RBD and N proteins, with neutralizing antibody titers increasing post infection and with disease severity. Memory B cells, including an atypical FCRL5+ T-BET+ memory subset, increased during the infection, especially in patients with mild disease. A…

education.field_of_studybiologyT cellImmunologyPopulationGeneral MedicineGZMBImmune systemImmunophenotypingmedicine.anatomical_structureHumoral immunityImmunologybiology.proteinmedicineAntibodyeducationCD8Science Immunology
researchProduct

Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE)

2018

Introduction: Murray sputum colour chart stratifies patients according to the presence of mucous (M), muco-purulent (MP) or purulent (P) sputum, and has not been validated in Bx yet. We aimed to validate this scale across a large Italian cohort of Bx patients. Methods: A secondary analysis of the IRIDE database was conducted including adults with Bx and daily sputum production enrolled across 13 Italian centres between 2014 and 2017. M vs. MP vs. P sputum producers were identified and clinical, functional and microbiological data were collected. Clinical outcomes during a two-year follow up period were evaluated in the Monza and Milan cohorts. A sensitivity analysis excluding COPD patients …

medicine.medical_specialtyBronchiectasisSputum colourCopd patientsbusiness.industrySputum Productionmedicine.diseaseDisease severityInternal medicineSecondary analysisCohortmedicineSputummedicine.symptombusiness
researchProduct

Primary ciliary dyskinesia in adults with bronchiectasis: Data from the Embarc registry

2018

Introduction: Primary ciliary dyskinesia (PCD) is an inherited cause of bronchiectasis where defects in motile cilia result in failure to clear mucus. Individuals have life-long productive cough and recurrent infections Methods: The embarc registry is a prospective pan-European observational study of adults with bronchiectasis. Data entered into the registry between March 2015 and Jan 2018 was assessed. Disease severity in PCD was compared to two age and gender matched cohorts, the first consisting of individuals with immune deficiency and a second with idiopathic disease. Results: 287/11204 individuals (2.6%) were reported to have PCD. 65% were female, reflecting the female predominance in…

medicine.medical_specialtyBronchiectasisbusiness.industryIncidence (epidemiology)Diseasemedicine.disease03 medical and health sciences0302 clinical medicineImmune system030228 respiratory systemInternal medicineCohortotorhinolaryngologic diseasesMotile ciliumMedicineSputum030212 general & internal medicinemedicine.symptombusinessPrimary ciliary dyskinesiaRespiratory infections
researchProduct

Can CAP guideline adherence improve patient outcome in internal medicine departments?

2008

The impact of compliance with Italian guidelines on the outcome of hospitallised community-acquired pneumonia (CAP) in internal medicine departments was evaluated. All Fine class IV or V CAP patients were included in this multicentre, interventional, before-and-after study, composed of three phases: 1) a retrospective phase (RP; 1,443 patients); 2) a guideline implementation phase; and 3) a prospective phase (PP; 1,404 patients). Antibiotic prescription according to the guidelines increased significantly in the PP. The risk of failure at the end of the firstline therapy was significantly lower in the PP versus the RP (odds ratio (OR) 0.83, 95% confidence interval (CI) 0.69-1.00), particular…

AdultMalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtycommunity acquired-pneumonia guideline internal medicineadherenceCritical Caremedicine.drug_classAntibioticsPopulationCommunity-acquired pneumoniaLevofloxacinInternal medicineInternal MedicinemedicineHumansProspective StudieseducationAgedRetrospective StudiesAged 80 and overeducation.field_of_studybusiness.industryPneumoniaOdds ratioGuidelineMiddle Agedmedicine.diseaseConfidence intervalCommunity-Acquired InfectionsPneumoniaTreatment OutcomeItalyFemaleGuideline Adherencebusinessmedicine.drugEuropean Respiratory Journal
researchProduct

The Severe Asthma Network in Italy: Findings and Perspectives

2019

Background Severe Asthma Network in Italy (SANI) is a registry of patients recruited by accredited centers on severe asthma. Objective To analyze epidemiological, clinical, inflammatory, functional, and treatment characteristics of severe asthmatics from the SANI registry. Methods All consecutive patients with severe asthma were included into the registry, without exclusion criteria to have real-life data on demographics, asthma control, treatments (including biologics), inflammatory biomarkers, and comorbidities. Results A total of 437 patients (mean age: 54.1 years, 57.2% females, 70.7% atopics, 94.5% in Global Initiative for Asthma severity step V) were enrolled into the study. The mean …

AdultMalemedicine.medical_specialtyRegistrySevere asthmaExacerbationBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Immunology and AllergyOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioComorbiditiesAtopy03 medical and health sciencesBronchiectasi0302 clinical medicineFood allergyInternal medicineLate-onset asthmaNasal polypsBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Adult; Aged; Asthma; Bronchiectasis; Comorbidity; Eosinophils; Female; Humans; Immunoglobulin E; Italy; Male; Middle Aged; Nasal Polyps; Registries; RhinitisMedicineHumansBronchiectasis Comorbidities Late-onset asthma Nasal polyps Registry SANI Severe asthma Immunology and AllergyImmunology and Allergy030212 general & internal medicineRegistriesAsthmaAgedRhinitisBronchiectasisbusiness.industryNasal polypSANIImmunoglobulin EMiddle Agedmedicine.diseaseAsthmaBronchiectasisEosinophils030228 respiratory systemItalyAsthma Control QuestionnaireFemaleComorbiditiebusinessMepolizumabmedicine.drug
researchProduct

Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study

2018

This study aimed to describe real-life microbiological testing of adults hospitalised with community-acquired pneumonia (CAP) and to assess concordance with the 2007 Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) and 2011 European Respiratory Society (ERS) CAP guidelines. This was a cohort study based on the Global Initiative for Methicillin-resistant Staphylococcus aureus Pneumonia (GLIMP) database, which contains point-prevalence data on adults hospitalised with CAP across 54 countries during 2015. In total, 3702 patients were included. Testing was performed in 3217 patients, and included blood culture (71.1%), sputum culture (61.8%), Legionella urinary anti…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtycommunity-acquired pneumoniaCommunity-acquired pneumoniaPatients4Concordance030106 microbiologyRespiratory Systemlcsh:MedicineSettore MED/10 - Malattie Dell'Apparato RespiratorioGUIDELINESPneumònia adquirida a la comunitatSputum cultureSerology03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaInternal medicinemedicineMANAGEMENTBlood culture030212 general & internal medicinePOPULATIONpneumonia Methicillin-resistant Staphylococcus aureus PneumoniaScience & Technologymedicine.diagnostic_testbusiness.industryMORTALITYlcsh:RMicrobiologia mèdicaOriginal ArticlesGuidelinePneumoniaMedical microbiologymedicine.diseaseMicrobiologicalETIOLOGYPneumoniaDiagnostic testingREQUIRING HOSPITALIZATIONbusinessLife Sciences & BiomedicineCohort studyERJ Open Research
researchProduct

One-Year Evolution of Symptoms and Health Status of the COPD Multi-Dimensional Phenotypes: Results from the Follow-Up of the STORICO Observational St…

2021

Raffaele Antonelli Incalzi,1 Francesco Blasi,2,3 Nicola Scichilone,4 Alessandro Zullo,5 Lucia Simoni,5 Giorgio Walter Canonica6 On Behalf of STORICO study group1Internal Medicine and Geriatrics Department Biomedical Campus University of Rome, Rome, Italy; 2Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; 3Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; 4DIBIMIS, University of Palermo, Palermo, Italy; 5Medineos Observational Research, Modena, Italy; 6Personalized Medicine Asthma & Allergy Clinic, Humanitas University, Humanitas &…

medicine.medical_specialtyphenotypeQuality of sleepHealth Statusquality of sleepSettore MED/10 - Malattie Dell'Apparato RespiratorioInternational Journal of Chronic Obstructive Pulmonary DiseaseDisease cluster03 medical and health sciencesDiseases of the respiratory systemPulmonary Disease Chronic Obstructive0302 clinical medicineQuality of lifeInternal medicineSurveys and Questionnairesevolutionmedicinecohort studyHumansIn patient030212 general & internal medicineOriginal ResearchCOPDRC705-779business.industryreal worldCohort study Evolution Phenotype Quality of life Quality of sleep Real worldGeneral Medicinemedicine.disease030228 respiratory systemquality of lifecohort study.Multi dimensionalObservational studybusinessCohort studyFollow-Up StudiesInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Asthma management in a specialist setting: Results of an Italian Respiratory Society survey.

2017

Abstract Background Asthma considerably impairs patients' quality of life and increases healthcare costs. Severity, morbidity, and degree of disease control are the major drivers of its clinical and economic impact. National scientific societies are required to monitor the application of international guidelines and to adopt strategies to improve disease control and better allocate resources. Aim to provide a detailed picture of the characteristics of asthma patients and modalities of asthma management by specialists in Italy and to develop recommendations for the daily management of asthma in a specialist setting. Method: A quantitative research program was implemented. Data were collected…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyConcordanceSocio-culturalePractice PatternsSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Index03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Retrospective StudieSurveys and QuestionnairesSeverity of illnessHealth caremedicineSurveys and QuestionnaireHumansPharmacology (medical)030212 general & internal medicinePractice Patterns Physicians'Adult; Aged; Asthma; Female; Humans; Italy; Male; Middle Aged; Practice Patterns Physicians'; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Quality of Life; SpecializationAsthmaAgedRetrospective StudiesModalitiesPhysicians'business.industryBiochemistry (medical)Retrospective cohort studyMiddle Agedmedicine.diseaseAsthmaPulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)030228 respiratory systemItalyTest scoreFamily medicinePhysical therapyQuality of LifeFemalebusinessHumanSpecializationPulmonary pharmacologytherapeutics
researchProduct

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe…

2021

Background: ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms. Methods: This phase 3b, randomised, double-blind, parallel-group, placebo-controlled ANDHI study was completed in adults (aged 18–75 years) with severe eosinophilic asthma with at least 2 exacerbations in the previous year, despite high-dose inhaled corticosteroid plus additional controllers, screening blood eosinophil counts of at least 150 cells per μL, and an Asthma Control Questionnaire 6 (ACQ-6) score of 1·5 or more. Patients who met eligibility criteria were randomly assigned (…

Pulmonary and Respiratory MedicineSpirometryAdultMalemedicine.medical_specialtyExacerbation[SDV]Life Sciences [q-bio]PopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboAntibodies Monoclonal Humanized03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInternal medicinemedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsPatient Reported Outcome MeasureseducationSinusitisAsthmaeducation.field_of_studymedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseBenralizumabAsthma3. Good healthEosinophils030228 respiratory systemchemistryAsthma Control QuestionnaireSpirometryDisease ProgressionQuality of LifeFemalebusiness
researchProduct

Characterization of circadian COPD symptoms by phenotype: Methodology of the STORICO observational study

2017

Abstract Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide. The symptoms of COPD are troublesome, variable, can occur during all parts of the 24-h day and have a substantial impact on patients' health status, quality of life and healthcare resource utilization. Reducing symptoms, improving health status and increasing physical activity are major goals in the management of stable COPD. In order to provide effective, patient-oriented care, patients should be evaluated on the basis of lung function, frequency of symptoms and patient-perceived impact of symptoms on their lives and treatment decisions made on a case-by-case basis. The …

Malemedicine.medical_specialtyPediatricsCross-sectional study24-Hour symptomLongitudinal StudieSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineQuality of life (healthcare)Surveys and QuestionnairesHealth careHealthcare resources utilizationmedicineInternal MedicineHumansCOPDSurveys and QuestionnaireRespiratory functionLongitudinal Studies030212 general & internal medicineIntensive care medicineCross-Sectional StudieCOPDbusiness.industrymedicine.diseaseComorbidityHealth-related quality of life (HRQoL)Circadian RhythmCross-Sectional StudiesPhenotype030228 respiratory systemItalyResearch DesignCohortDisease ProgressionQuality of LifeObservational studyFemalebusinessHuman
researchProduct

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

2018

Abstract Background The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results At least 1 risk factor for immunocompromis…

0301 basic medicineMalePediatricsEtiologyMultidrug-resistant pathogenMRSAPneumocystis pneumoniaPneumònia adquirida a la comunitatHOSPITALIZED-PATIENTS0302 clinical medicineCommunity-acquired pneumoniaRisk FactorsPrevalenceMedicine030212 general & internal medicinePNEUMOCYSTIS PNEUMONIAArticles and CommentariesAged 80 and overRespiratory tract infectionsAnemia AplasticMiddle Aged3. Good healthCommunity-Acquired InfectionsEuropeInfectious DiseasesImmunocompromise; Microbiology; MRSA; Multidrug-resistant pathogens; PneumoniaEtiologiaHematologic NeoplasmsFemaleBLOOD-STREAM INFECTIONSLung TransplantationMicrobiology (medical)medicine.medical_specialtyAsiaNeutropeniaCommunity-acquired pneumonia030106 microbiologyRESPIRATORY-TRACT INFECTIONSHematologic NeoplasmsSettore MED/10 - Malattie Dell'Apparato RespiratorioTRANSPLANT RECIPIENTSDISEASES-SOCIETYMicrobiology03 medical and health sciencesImmunocompromised HostPneumonia BacterialMANAGEMENTHumanspneumoniaBACTERIAL PNEUMONIAImmunocompromiseAgedAcquired Immunodeficiency Syndromebusiness.industrymicrobiologyBacterial pneumoniaAustraliaPneumoniamedicine.diseaseMultidrug-resistant pathogensPneumoniamultidrug-resistant pathogensMycosesBacteremiaAfricaEtiologyRISK-FACTORSimmunocompromiseAmericasbusinessClinical Infectious Diseases
researchProduct

Severe asthma: One disease and multiple definitions

2021

Abstract Introduction There is, so far, no universal definition of severe asthma. This definition usually relies on: number of exacerbations, inhaled therapy, need for oral corticosteroids, and respiratory function. The use of such parameters varies in the different definitions used. Thus, according to the parameters chosen, each patient may result in having severe asthma or not. The aim of this study was to evaluate how the choice of a specific definition of severe asthma can change the allocation of patients. Methods Data collected from the Severe Asthma Network Italy (SANI) registry were analyzed. All the patients included were then reclassified according to the definitions of U-BIOPRED,…

Pulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaSevere asthmaImmunologyNiceDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioArticlePulmonary function testingInternal medicineBiological treatment; Classification; Definition; Severe asthmamedicineImmunology and AllergyRespiratory functioncomputer.programming_languageSevere asthma; Classification; Definition; Biological treatmentBiological therapiesbusiness.industrySettore MED/09 - MEDICINA INTERNADefinitionRC581-607ClassificationSevere asthma Classification Definition Biological treatmentBiological treatment Classification Definition Severe asthmaImmunologic diseases. AllergybusinessBiological treatmentcomputer
researchProduct

The COPD multi-dimensional phenotype: A new classification from the STORICO Italian observational study.

2019

BackgroundThis paper is aimed to (i) develop an innovative classification of COPD, multi-dimensional phenotype, based on a multidimensional assessment; (ii) describe the identified multi-dimensional phenotypes.MethodsAn exploratory factor analysis to identify the main classificatory variables and, then, a cluster analysis based on these variables were run to classify the COPD-diagnosed 514 patients enrolled in the STORICO (trial registration number: NCT03105999) study into multi-dimensional phenotypes.ResultsThe circadian rhythm of symptoms and health-related quality of life, but neither comorbidity nor respiratory function, qualified as primary classificatory variables. Five multidimension…

MalePulmonologyPhysiologyComorbidityAnxietyPathology and Laboratory MedicineCohort StudiesPulmonary Disease Chronic ObstructiveMathematical and Statistical TechniquesQuality of lifeMedicine and Health SciencesCoughingCluster AnalysisRespiratory functionPublic and Occupational HealthAged 80 and overCOPDMultidisciplinaryDepressionApplied MathematicsSimulation and ModelingQStatisticsRMiddle AgedExploratory factor analysisCircadian RhythmBody FluidsCircadian RhythmsPhenotypeItalyPhysical SciencesAnxietyMedicineFemalemedicine.symptomAnatomyFactor AnalysisAlgorithmsCohort studyResearch Articlemedicine.medical_specialtyScienceMemory EpisodicChronic Obstructive Pulmonary DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioResearch and Analysis MethodsClustering AlgorithmsSigns and SymptomsDiagnostic MedicineInternal medicinemedicineCOPDHumansStatistical MethodsAgedbusiness.industryBiology and Life SciencesPhysical Activitymedicine.diseaseComorbidityrespiratory tract diseasesMucusDyspneaCoughQuality of LifeObservational studybusinessFactor Analysis StatisticalSleepPhysiological ProcessesChronobiologymultiple phenotypesMathematicsPloS one
researchProduct

Use of high flow nasal cannula in patients with acute respiratory failure in general wards under intensivists supervision: a single center observatio…

2022

Abstract Background Few data exist on high flow nasal cannula (HFNC) use in patients with acute respiratory failure (ARF) admitted to general wards. Rationale and objectives To retrospectively evaluate feasibility and safety of HFNC in general wards under the intensivist-supervision and after specific training. Methods Patients with ARF (dyspnea, respiratory rate-RR > 25/min, 150 < PaO2/FiO2 < 300 mmHg during oxygen therapy) admitted to nine wards of an academic hospital were included. Gas-exchange, RR, and comfort were assessed before HFNC and after 2 and 24 h of application. Results 150 patients (81 male, age 74 [60–80] years, SOFA 4 [2–4]), 123 with de-novo ARF underwent HFNC wi…

MaleRespiratory Distress SyndromeNoninvasive VentilationOxygen Inhalation TherapyARFHFNCOxygenGeneral-wardsDyspneaAHRFICU-supervisionPatients' RoomsCannulaHumansSafetyRespiratory InsufficiencyAgedRetrospective Studies
researchProduct

Quality standards for the management of bronchiectasis in Italy: A national audit

2016

Although historically considered a neglected disease, bronchiectasis has become a disease of renewed interest over recent decades in light of an increase in prevalence and a substantial burden on healthcare systems. In 2010, the British Thoracic Society (BTS) published guidelines on the management of bronchiectasis in adults, along with specific quality standards. To date, these represent the only quality standards available in Europe. These have been tested over a number of years in the UK with progressive improvements in the standard of care. No national guidelines are available in Italy and no indications on which guideline should be followed have been given by the Italian Society of Res…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtybronchiectasismedia_common.quotation_subjectSymptom Flare UpMedical auditSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciences0302 clinical medicinemedicinePrevalenceHumansQuality (business)Pseudomonas Infections030212 general & internal medicineIntensive care medicineNational auditmedia_commonAgedMedical AuditBronchiectasisbusiness.industryMedicine (all)Middle Agedmedicine.diseaseSymptom Flare UpAnti-Bacterial AgentsPatient Care Management030228 respiratory systemItalyNeeds assessmentPseudomonas aeruginosaFemalebusinessMedicine (all); Pulmonary and Respiratory MedicineNeeds Assessment
researchProduct

Genuair® Usability Test: Results of a National Public Survey of the Elderly

2016

Proper use of inhaler devices may be problematic in elderly patients due to age-related difficulties. A survey was administered to elderly patients to investigate the usability of the Genuair® device and patients' subjective viewpoint on the device. A representative sample of the Italian population aged ≥ 65 years was completed with a pre-defined sample of 89 patients with hand arthritis/arthrosis. Of 526 respondents, 88 were not self-sufficient. Only the replies of the 438 self-sufficient respondents were analyzed. A total of 107 participants (24%) reported having respiratory diseases, and 81 of these (76%) were users of inhaler devices. After the first test, the device was considered “pra…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorsSample (statistics)Settore MED/10 - Malattie Dell'Apparato Respiratorioelderly03 medical and health sciences0302 clinical medicinePatient satisfactionPatient Education as TopicSurveys and QuestionnairesmedicineHumansadherence030212 general & internal medicineAgedAged 80 and overbusiness.industryArthritisNebulizers and VaporizersInhalerUsabilityPublic surveyadherence; elderly; inhaler device; usability; Pulmonary and Respiratory MedicineHandItalian populationTest (assessment)usabilityItaly030228 respiratory systemPatient SatisfactionHand arthritisPhysical therapyinhaler deviceFemalebusinessCOPD: Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct

Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?

2021

severe asthma2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaImmunologyComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioCOVID-19 severe asthma COPDNOHumans; SARS-CoV-2; Asthma; COVID-19Internal medicineCorrespondencemedicineCOPDImmunology and AllergyHumansAsthmaCOVIDbusiness.industrySARS-CoV-2COVID-19asthmamedicine.diseaseItalybusiness
researchProduct

Additional file 1: of Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective

2018

Table A: Tables with testing frequencies for specific atypical pathogens across continents (A1: Testing frequencies for C. pneumoniae across continents; A2: Testing frequencies for M. pneumoniae across continents; A3: Testing frequencies for L. pneumophila across continents).- Brief description of the data: a table in three parts reporting data about frequency of testing for different atypical pathogens across different continents. (DOC 50â kb)

researchProduct

Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study

2019

Abstract Background Chronic Obstructive Pulmonary Disease (COPD) encompasses various phenotypes that severely limit the applicability of precision respiratory medicine. The present investigation is aimed to assess the circadian rhythm of symptoms in pre-defined clinical COPD phenotypes and its association with health-related quality of life (HR-QoL), the quality of sleep and the level of depression/anxiety in each clinical phenotype. Methods The STORICO (NCT03105999) Italian observational prospective cohort study enrolled COPD subjects. A clinical diagnosis of either chronic bronchitis (CB), emphysema (EM) or mixed COPD-asthma (MCA) phenotype was made by clinicians at enrollment. Baseline e…

MaleChronic bronchitisTime FactorsHealth StatusAnxietyHospital Anxiety and Depression ScaleSeverity of Illness IndexHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineSurveys and QuestionnairesForced Expiratory VolumeClinical phenotypeMedicineSurveys and QuestionnaireRespiratory function030212 general & internal medicineProspective StudiesProspective cohort studyLungDepression (differential diagnoses)COPDDepressionMiddle AgedCircadian RhythmPhenotypeItalyAnxietyFemalemedicine.symptom24-hour symptoms Clinical phenotype Real-world Respiratory functionResearch ArticleHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveTime FactorSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease03 medical and health sciencesInternal medicineHumansAsthma24-hour symptoms; Clinical phenotype; Real-world; Respiratory function; Aged; Anxiety; Depression; Female; Forced Expiratory Volume; Health Status; Humans; Italy; Lung; Male; Middle Aged; Phenotype; Prospective Studies; Pulmonary Disease Chronic Obstructive; Severity of Illness Index; Sleep; Surveys and Questionnaires; Time Factors; Circadian Rhythm; Quality of LifeAgedlcsh:RC705-77924-hour symptomsbusiness.industryCorrectionlcsh:Diseases of the respiratory systemmedicine.disease24-hour symptomProspective Studie030228 respiratory systemReal-worldQuality of LifebusinessSleepRespiratory function
researchProduct

COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments

2020

To the Editor Since the end of February 2020 Italy, first non- Asian Country, has reported an ever increasing number of COronaVIrus Disease 19 (COVID-19) patients, which has reached over 200,000 confirmed Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infected subjects and resulted in more than 34000 deaths (data updated to June 19th, 20201).Patients with asthma are potentially more severely affected by by SARS-CoV-2 infection 2 and it is well established that respiratory viral infections are associated with severe adverse outcomes in patients with asthma, including increased risk of asthma exacerbation episodes 3. Nonetheless, according to the epidemiological studies publishe…

severe asthmamedicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 Severe Asthma Network in Italy inflammationCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaPopulationImmunologyMEDLINEOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioNOInternal medicineDiabetes mellitusSeverity of illnessmedicineImmunology and AllergyRisk factorLetters to the EditoreducationLetter to the EditorAsthmaeducation.field_of_studybusiness.industryIncidence (epidemiology)Mortality rateCOVID-19medicine.diseaseComorbiditySevere Asthma Network in ItalyinflammationCohortbusinessMepolizumabmedicine.drug
researchProduct